The Fellow on Call: The Heme/Onc Podcast

This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology , The ASH Trainee Council, and Hematopoiesis!

For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!

This time, we welcome two amazing guests, Dr. Hetty Carraway, Director of the Leukemia Program and the Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute at The Cleveland Clinic, and Dr. Alfred Lee, Chief of Classical Hematology at Yale School of Medicine, for our inaugural episode where we discuss the importance of mentorship and ask them all the questions most of us have always wondered but are too afraid to ask our mentors. A MUST listen for all trainees!

** This episode is created in partnership with The American Society of Hematology (hematology.org), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoeisis (https://www.hematology.org/education/trainees/fellows/hematopoiesis)

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

This week, we begin our discussion about treatment of multiple myeloma, focusing on the first-line setting. Once again, a lot has changed in this space over the last few years, most notably the standards of care (now quadruplet regimens instead of triplet regimens!). We break down the data and how to help you practically approach your treatment planning for your patient with newly diagnosed multiple myeloma.

Content:

- What are the phases of treatment for multiple myeloma

- What are our current treatment standards of care?

- How do we select the agents to include in our first-line regimens?

- How do we stratify patients into quadruplet vs. triplet eligible? What about transplant eligible vs. ineligible?

** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

This week, we introduce a new episode for our myeloma series, this time focusing on risk stratification and response criteria. The initial workup and surveillance labs are expansive, but all of the studies we do have a purpose.

Many present-day studies also use “minimal residual disease” (MRD) testing. What does this mean? How do we use this?

We go through all of this and more in this incredibly high yield episode.

Content:

- How do we risk stratify patients with newly diagnosed MM?

- What are the criteria used to risk stratify? Why does this matter?

- How do we define response to treatment? Progression?

- What is the role of "minimal residual disease" in myeloma?

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!

Content:

- What are common drugs we use in "triplet regimens"? "quadruple therapy"?

- What considerations must we take into account when prescribing commonly used medications in myeloma?

- How should we counsel our patients?

- What about supportive care?

- How and when do we make dose adjustments?

- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see

Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!

Content:

- What are common drugs we use in "triplet regimens"? "quadruple therapy"?

- What considerations must we take into account when prescribing commonly used medications in myeloma?

- How should we counsel our patients?

- What about supportive care?

- How and when do we make dose adjustments?

- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see

Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

The way that we think about smoldering multiple myeloma (SMM) has continued to see evolution in the plasma cell dyscrasia space. If this diagnosis portends a higher risk of developing multiple myeloma, how should we manage patients to prevent possible end-organ damage? Is it a one-size-fits-all approach or are there some patients who are higher risk for progression than others? We cover this and so much more in this new episode!

This episode is brought to you by Primum

Content:

- What is smoldering multiple myeloma (SMM)?

- What are higher risk features of SMM?

- What are landmark studies in SMM?

- To treat or not to treat?

** This episode is brought to you by Primum: http://primum.co/fellows

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

In today’s episode, we continue our myeloma series, this time we’ll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!

Content:

- Defining MGUS

- Discussing risk of progression of MGUS to MM

- How to interpret free light chains in renal failure

- How do we monitor MGUS patients?

- When do we do additional testing in MGUS?

- What is smoldering myeloma?

- What are myeloma defining events?

- How do we risk stratify SM patients?

- How do we monitor SM patients?

Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co

** Want to review the show notes for this episode and others? Check out our website:

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

It’s been 3 years since our last myeloma series updates and the reality is, a lot has changed! Instead of releasing an updates episode, we are redoing our prior myeloma series to make sure that you, our listeners, can follow along the way you always have.

In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma cell dyscrasias and having our initial discussion about monoclonal gammopathy of undetermined significance (MGUS).

Contents:

- What is a plasma cell ?

- What is a plasma cell dyscrasia?

- What is an "SPEP"?

-What is "immunofixation"?

-What are "serum free light chains"?

-Checking UPEP

-Does everyone need a bone marrow biopsy and/or additional workup?

-What is MGUS?

** Want to review the show notes for this episode and others? Check out our website:

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series.

You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart.

Episode contents:

- What are "CAR T" and "bispecific antibodies"?

- What are the approved agents?

- Selection of one therapy over another

- Side effect profiles

** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week’s conversation!

Episode contents:

- What is the role of rituximab maintenance therapy?

- What does surveillance after therapy look like?

- What are options for treatment of patients who have relapsed follicular lymphoma?

** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast